THE EFFECTIVENESS OF NIVOLUMAB AND CHEMOTHERAPY AGAINST LUNG AND STOMACH CANCER
It is known that immunotherapy is a cancer treatment that stimulates the body’s defenses to fight cancer by destroying cancer cells, there are several types of immunotherapies, one of them helps the immune system to stop or slow down growth of cancer cells, others help the immune system destroy cancer cells or stop cancer from spreading to other parts of the body. Immunotherapy treatments can be used alone or in combination with other cancer treatments (Cancer.Net 05/2020).
Almost the majority of patients usually have surgeries as a treatment against lung cancer, but unfortunately it mostly comes back, but after a study called CheckMate 816, it has been discovered that treatment with the immunotherapy drug nivolumab (opdivo) and chemotherapy combined before surgery effectively delay the progression or return of cancer, so patients who have received this combination treatment have lived longer and without serious complications than those who have not.
Unfortunately, it is difficult to detect lung cancer before it spreads outside the lungs, patients have surgery to remove the tumor, but sadly even when the cancer is in its early stage and the entire tumor is removed, the cancer comes back.
FDA has approved nivolumab as a neoadjuvant treatment in combination with chemotherapy for people with early-stage lung cancer. Scientific advances in lung cancer are long overdue, but are noted for their gargantuan advances. Combination immunotherapy is known to be a standard treatment that will almost certainly improve overall survival for people with early-stage disease. The results of the CheckMate 816 study were presented in April at the annual meeting of the American Association for Cancer Research (AACR) and published at the same time in the New England Journal of Medicine (NEJM).
This is how immunotherapy is revolutionizing cancer treatment. Preliminary data talk about its efficacy in several malignant diseases, such as lung cancer, which is one of the most common. Immunotherapy, either alone or in combination with chemotherapy, has significantly improved the results of patients fighting cancer in general.
It has also been found that some people with advanced stomach cancer live longer if they receive initial treatment with nivolumab (Opdivo) and chemotherapy, this study is called CheckMate 649, but the latest results also demonstrate that this approach can also benefit early-stage patients. It is known that the majority of patients do very well with this new combination therapy and have few side effects.
Therefore, we must know that it is not possible to prevent all cancers, however, you can take measures that can reduce the risks of contracting this disease, such as do not smoke, avoid smoke from people who smoke, avoid or limit exposure to cancer-causing agents, eat healthy foods, in general try to lead a healthy life without excesses.
References:
El nivolumab es eficaz contra el cáncer de estómago avanzado. (2020, 3 December). Instituto Nacional del Cáncer. https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog/2020/cancer-estomago-inmunoterapia-nivolumab
Qué es la inmunoterapia. (2022, 3 June). Cancer.Net. https://www.cancer.net/es/desplazarse-por-atenci%C3%B3n-del-c%C3%A1ncer/c%C3%B3mo-se-trata-el-c%C3%A1ncer/inmunoterapia-y-vacunas/qu%C3%A9-es-la-inmunoterapia
The post THE EFFECTIVENESS OF NIVOLUMAB AND CHEMOTHERAPY AGAINST LUNG AND STOMACH CANCER appeared first on Williams Cancer Institute.
source https://williamscancerinstitute.com/the-effectiveness-of-nivolumab-and-chemotherapy-against-lung-and-stomach-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=the-effectiveness-of-nivolumab-and-chemotherapy-against-lung-and-stomach-cancer
No comments:
Post a Comment